Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3832218 | 0.85 | GRM5 (0.61) | GRM5ALDH1A1GAAPKMTP53 | |
| SCHEMBL1346789 | 0.85 | GRM5 (0.63) | GRM5ALDH1A1GAATP53MAPT | |
| SCHEMBL15307431 | 0.82 | GRM5 (0.58) | GRM5ALDH1A1GAAPKMTP53 | |
| SCHEMBL3831325 | 0.76 | GRM5 (1.00) | GRM5ALDH1A1TP53LMNATHRB | |
| SCHEMBL17962942 | 0.76 | GRM5 (0.51) | GRM5ALDH1A1GAAPKMTP53 | |
| SCHEMBL28057136 | 0.75 | ERN1 (0.51) | GRM5GAAPKMTP53MAPT | |
| SCHEMBL3832192 | 0.75 | GRM5 (0.77) | GRM5ALDH1A1TP53LMNAMAPT | |
| Hydrochloric Acid SCHEMBL3834927 | 0.75 | GRM5 (0.98) | GRM5ALDH1A1TP53LMNATHRB | |
| Hydrochloric Acid SCHEMBL3830982 | 0.74 | GRM5 (0.75) | GRM5ALDH1A1TP53LMNAMAPT | |
| SCHEMBL10451409 | 0.73 | ALDH1A1 (0.59) | GRM5ALDH1A1GAAPKMTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270371-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT. (HU) | 2009-10-29 | — | — | US | disclosed |
| EP-1962849-B1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT (HU) | 2009-09-30 | — | — | EP | disclosed |
| CN-101346141-A | Quinoline derivatives useful in the treatment of MGLUR5 receptor-mediated disorders | RICHTER GEDEON NYRT (HU) | 2009-01-14 | — | — | CN | disclosed |
| EP-1962849-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | Richter Gedeon NYRT (HU) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007072093-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT. (HU) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270371-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | GRM5, GRIK5, GRM1 | GRM5 1/4885ALDH1A1 2356/4885GAA 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.